KRISTEN SWEET: Open Payments
NPI 1407093313 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$279 in 14 payments from 8 companies in 2025. Trend: 2023 $793 · 2024 $606 · 2025 $279
Food & beverage: $279
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 2 | $49 |
| Amgen Inc. | 2 | $44 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Novo Nordisk Inc | 1 | $19 |
Products named: REPATHA, LEQVIO, LifeVest, JARDIANCE, CDS broad portfolio offering, ONPATTRO, VERQUVO, Wegovy.
Industry payments across OK — which companies pay providers there.
